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Pertussis incidenceThe Accelerated Development of VAccine benefit-risk Collaboration in Europe (ADVANCE), a public-
private consortium, implemented and tested a distributed network system for the generation of evidence
on the benefits-risks of marketed vaccines in Europe. We tested the system by estimating the incidence
rate (IR) of pertussis and pertussis-related complications in children vaccinated with acellular (aP) and
whole-cell (wP) pertussis vaccine. Data from seven electronic databases from four countries (Denmark:
AUH and SSI, Spain: SIDIAP and BIFAP, UK: THIN and RCGP RSC and Italy: Pedianet) were included in a
retrospective cohort analysis. Exposure was defined as any pertussis vaccination (aP or wP). The
follow-up time started 14 days after the first dose. Children who had received any pertussis vaccine from
January 1990 to December 2015 were included (those who switched type, or had unknown type were
excluded). The outcomes of interest were confirmed or suspected pertussis and pertussis-related pneu-
monia and generalised convulsions within one month of pertussis diagnosis and death within three
months of pertussis diagnosis. The cohort comprised 2,886,367 children 5 years of age. Data on wP
and aP vaccination were available in three and seven databases, respectively. The IRs (per 100,000





B32 M. Tin Tin Htar et al. / Vaccine 38 (2020) B31–B37CI: 1.07; 1.23), and the trends over time was consistent with those observed from national surveillance
databases for confirmed pertussis. The pertussis IRs decreased as the number of wP and aP vaccine doses
increased. Pertussis-related complications were rare (89 pneumonia, 7 generalised convulsions and no
deaths) and their relative risk (vs. non-pertussis) could not be reliably estimated. The study demonstrated
the feasibility of the ADVANCE system to estimate the change in pertussis IRs following pertussis vacci-
nation. Larger sample sizes would provide additional power to compare the risk for complications
between children with and without pertussis. The feasibility of vaccine-type specific effectiveness studies
may be considered in the future.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
ADVANCE is a public-private collaboration aiming to develop
and test a system for rapid benefit-risk monitoring of vaccines
using existing healthcare databases in Europe using a distributed
network approach similar to that used in other post-licensure vac-
cine safety studies [1,2]. The processes and systems for generating
the data required to perform benefit/risk (B/R) monitoring of vac-
cines were developed and evaluated through proof of concept
(POC) studies [3–6]. These POC studies consisted of four individual
studies assessing the feasibility of generating data for coverage,
benefit, risk, and the benefit-risk model. The research question
was considered as a proxy for the introduction of a hypothetical
new vaccine when benefit-risk monitoring would be needed,
which is one of the scenarios in which the ADVANCE system could
be used in the future. For this purpose, we assessed if the initial
benefit-risk profile of pertussis vaccines was maintained after the
switch from whole cell pertussis (wP) vaccines to acellular pertus-
sis (aP) vaccines. It should be noted that these POC studies were
undertaken for system testing and not to inform clinical, regulatory
or public health decisions on pertussis vaccination.
Here we present the results from the benefit POC study. The
specific objective was to determine the feasibility of using avail-
able electronic healthcare databases to estimate the incidence of
pertussis following different doses of wP and aP vaccination and
pertussis-associated complications (pneumonia, generalised con-
vulsions and death) following pertussis disease to inform the ben-
efit/risk model [7].2. Material and methods
2.1. Study design
Full details of the study design can be found in the protocol, reg-
istered in the ENCePP (EUPAS) registry [6]. This was a retrospective
dynamic cohort analysis.
2.2. Electronic healthcare databases used
Seven of the 19 European healthcare databases identified in
ADVANCE participated in this POC study from Denmark (n = 2),
Spain (n = 2), UK (n = 2) and Italy (n = 1) (Table 1) [8]. Details about
the extraction, management, transformation, sharing, and analyses
of the data using the ADVANCE system workflows and methodol-
ogy can be found in paper 2 in this supplement [9].
2.3. Population studied
The source population consisted of children in the participating
databases that were followed from first dose of pertussis vaccina-
tion until administration of the pre-school-entry booster or their
sixth birthday (or death or transfer out of the database), which ever
occurred first. To be eligible, date of birth and start and end offollow-up dates had to be available, i.e., no missing dates were
allowed. Day, month and year were required for start and end of
follow-up dates but date of birth could be rounded to an arbitrary
day in the registered birth month. Children registered within three
months of birth with a logical recorded series of pertussis vaccina-
tion (i.e., Dose 0 before Dose 1, etc.) were eligible. Only children
who had received at least one dose of a single type of pertussis vac-
cine, i.e., only aP or wP, were included; those who switched from
one type to the other or who had any doses with unknown type
were excluded. The study period start and end dates varied
between databases, depending on data availability (Table 2).
2.4. Exposure
The exposure of interest was aP- or wP-containing vaccine
(either as a single component or part of a multivalent vaccine pro-
duct). We defined four periods of vaccine exposure as follows: aP-0
– first 14 days after the first dose (when children were considered
not to be protected yet); aP-1 – from 14 days post-dose 1 to
14 days post-dose 2; aP-2 – from 14 days post-dose 2 to 14 days
post-dose 3; and aP-3 – from 14 days post-dose 3 until the end
of follow-up.
2.5. Outcomes analysed
The outcomes analysed in children from first dose up to school-
entry booster vaccination, 6th birthday, death or leaving the data-
base, were the incidence rates (IRs) of pertussis following pertussis
vaccination, non-fatal pertussis-related convulsions and pneumo-
nia leading to hospitalisation within 1 month of pertussis diagno-
sis, and death within 3 months of pertussis diagnosis.
A set of codes were generated to identify confirmed and possi-
ble pertussis events in the databases using the ADVANCE
Codemapper to map codes to the different coding systems used
in the databases: 033.9; 484.3 (ICD-9), A37 (ICD-10), A33y,
A33yz; A33z.; Ayu39; Ayu3A; H243.; X70I8; XE0Qw; XE0Qw;
XM00D (Read version 2 or Clinical Terms version 3), A33 Ayu39;
Ayu3A; H243(REAd-V3) and R71 (ICPC) (Supplementary Table S1)
[10,11]. The database codes used for pertussis-associated compli-
cations are summarised in Supplementary Table S1.
2.6. Statistical analyses
Incidence rates (IRs) for pertussis (per 1000 person-years) were
calculated by dividing the number of events by the person-time of
follow-up, overall, by year and by dose for children who had
received at least one dose. This was done by calendar year and
by exposure period. For the analyses of pertussis complications
children diagnosed with pertussis after having received one or
more doses of pertussis vaccine were identified (‘break-through’
pertussis cases) and were matched on birth-year and month to
100 children who had been vaccinated, but had not been diagnosed
with pertussis (non-pertussis controls). Kaplan-Meier curves were
Table 1
Overall numbers of individuals in each database and numbers of children aged <6 years included in the benefit cohort.
Denmark UK Spain Italy
AUH SSI RCGP RSC THIN BIFAP SIDIAP PEDIANET* Total















Number of persons in full population file (any age) 1,725,165 7,512,032 3,017,610 11,696,261 7,541,864 7,096,695 9708 38,599,335
Number of children (0–5 years) included in the final benefit
cohort
143,399 1,004,854 151,764 770,849 288,476 519,330 7695 2,886,367
AUH: Aarhus University Hospital; SSI; Statens Serum Institut; RCGP RSC: Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC); THIN: The
Health Improvement Network; BIFAP: Base de Datos Para la Investigación Farmacoepidemiológica en Atención Primaria; SIDIAP: Institut Universitari d’Investigació en
Atenció Primària Jordi Gol.
* PEDIANET included only children 0–14 years of age.
Table 2
Exposure, follow-up time, number of pertussis cases and pertussis incidence rates (per 1000 person-years) in children aged 0–5 years who had received at least one dose of
whole-cell pertussis (wP) or acellular pertussis (aP) containing vaccine (follow-up started 14 days after the first dose)*.
Database
(country)








Incidence rate/1000 person-years (95%
CI)
AUH (Denmark) 1997 aP 556,048 83 0.15 (0.12; 0.19)
SSI (Denmark) 1997 aP 4,155,943 2820 0.68 (0.65; 0.70)
RCGP RSC (UK) 2004 aP + wP 474,732 109 0.23 (0.19; 0.28)
THIN (UK) 2004 aP + wP 2,229,848 487 0.22 (0.20; 0.24)
BIFAP (Spain) 2000–2004 aP + wP 370,343 229 0.62 (0.54; 0.70)
SIDIAP (Spain) 2000–2004 aP 751,786 862 1.15 (1.07; 1.23)
PEDIANET (Italy) Before 1996 aP 37,343 25 0.67 (0.45; 0.99)
* Children were followed up until 6th birthday, pre-school booster dose, death, leave database or the end of the study, whichever occurred earliest.
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monia, convulsions and death. Cox regression models for these
outcomes were fitted to compare children with pertussis diagnosis
and their controls. Using the probabilities estimated with the
Kaplan-Meier method and the hazard ratios obtained from the
Cox regression, ‘excess probabilities’ of the different events were
calculated, with their 95% CIs.
3. Results
3.1. Characteristics of population
The source population included over 38 million persons of all
ages in seven databases from Denmark, Italy, Spain and the UK
(4 national databases and 3 regional databases) (Table 1). A total
of 2,886,367 children <6 years of age were included in the study
cohort. The national Danish database SSI contributed data for
1,004,854 children (35%) and the national UK database, THIN, con-
tributed data for 770,849 children (27%). The smallest contribution
was from the Italian regional paediatric database, PEDIANET,
which contributed data for 7695 children (0.3%).
Data on aP vaccination were available in all databases and data
for wP vaccination were available in three (RCGP RSC, THIN, BIFAP)
(Table 2).
3.2. Incidence of pertussis
A total of 4615 pertussis cases were identified in the study
cohort over 8,576,043 person-years of follow-up with 79.6% of
the follow-up time being post-dose 3. The overall incidence
(/1000 person-years) for pertussis in the study cohort (aged 0 to
5 years) ranged from 0.15 (95% CI: 0.12; 0.19) in the AUH database
to 1.15 (95% CI: 1.07; 1.23) in the SIDIAP database (Table 2). The
incidence rates of pertussis from 1st dose to 5 years of age by data-
base and year in children who had received at least one dose are
summarised in Fig. 1 and Supplementary data Table S2. The pertus-
sis IRs decreased with the number of doses of vaccines received inmost databases (Fig. 2). The IRs after one dose of wP and aP ranged
from 0 to 2.08 and 0.46 to 2.69, respectively. Post-dose 3 the IRs
ranged from 0.19 to 0.28 and 0.03 to 0.68, respectively.
3.3. Complications following pertussis diagnosis
There were 89 cases of pneumonia within one month after per-
tussis diagnosis, with no cases in the UK (RCGP RSC and THIN) and
Italian (PEDIANET) databases. Thus the HRs for pneumonia in
breakthrough cases compared with vaccinated non-pertussis con-
trols was calculated with data from the two Danish and two Span-
ish databases (Table 3). The HRs of pneumonia in pertussis cases
versus children without pertussis ranged from 4.1 (95% CI: 2.2;
7.8) to 24.6 (95% CI: 19.1; 31.7). There were seven cases of gener-
alised convulsions within one month after pertussis diagnosis (five
in SSI and two cases in SIDIAP), with a relative risk of 1.99 (95% CI:
0.8; 4.8) in SSI and 4.6 (95% CI: 1.1; 19.2) in SIDIAP (Table 3). No
deaths occurred within three months of pertussis diagnosis there-
fore the HRs were not calculated (Table 3).
The planned analyses for pertussis-related complications in five
age groups (2–3 months, 4–5 months, 6–11 months, 12–
23 months, 24 months or older) could not be done because of the
low number of events. The ‘excess probabilities’ of the different
complication events were calculated but were too small to be reli-
ably interpreted (data not shown).
4. Discussion
In this study we showed it was possible to estimate pertussis
IRs following wP or aP vaccination overall, over time and by the
number of doses received demonstrating that data from the partic-
ipating healthcare databases can be used to estimate vaccine effec-
tiveness. We observed that the IRs for pertussis decreased as the
number of aP and wP doses increased. This is consistent with our
current knowledge, i.e. protection increases with the number of
doses [12]. However, even with data from seven databases




































































































































































































































































Fig. 1. Pertussis incidence rate per 1000 person-years for children who had received at least one dose of pertussis vaccine by database and year followed from 1st dose to age
5 years.
B34 M. Tin Tin Htar et al. / Vaccine 38 (2020) B31–B37possible to estimate HRs reliably for pertussis-related complica-
tions in vaccinated children who developed pertussis versus those
without pertussis due to the low number of cases and the low inci-
dence of complications in these cases. Only 4615 children devel-
oped pertussis following vaccination among the 2.9 million
vaccinated children and only 89 of them developed pneumonia
and 7 developed generalised convulsions within one month of
the pertussis diagnosis and none died within three months of the
pertussis diagnosis. Low numbers of events were also observed
in the comparison group (children who did not develop pertussis
after vaccination). Consequently, we were not able to calculate
HRs for all outcomes in all databases, and we could not calculate
the HRs by vaccine type, i.e. aP or wP vaccines. Importantly, in this
study we estimated the incidence of pertussis in vaccinated chil-
dren over time for different periods with different programmes
and heterogeneous vaccine coverage rates. However, we intention-
ally did not attempt to estimate the vaccine effectiveness, or to
estimate the impact of the vaccination programme as incidence
rate reduction between two different time points (wP vaccine peri-
ods compared to those aP periods.
Our results show that the incidence of pertussis in children who
had received at least one dose of pertussis vaccine from 2003
onwards was lowest in the UK and highest in Spain. We did not
observe any major differences between the results from the two
UK databases, THIN and RCGP RSC, in the same calendar years.
Although these databases do not cover the whole population, they
are representative of the UK population, with a small overlap in
practices captured by both databases [13,14]. The trend observed
in our study was similar to that reported for confirmed pertussis
observed over the last decade in children aged <5 years in the
UK, although our IRs were lower since they are for vaccinated chil-
dren only, whereas the reported national rates were for the whole
population, vaccinated or not [15,16].
For Denmark, we observed a similar trend over time for the per-
tussis incidence rate in the SSI (national) and AUH (regional) data-bases, except we observed peaks in the incidence rates in 2004 and
2012 in the SSI database, similar to those reported for laboratory-
confirmed pertussis in the whole Danish population [17]. The per-
tussis IRs were generally higher in the national SSI database than in
the regional AUH database; this may be due to differences in pop-
ulation dynamics. For Spain, a higher incidence of pertussis was
observed in the regional SIDIAP database than in the multi-
regional BIFAP database but the trends since 2001 in the two data-
bases were similar. The observed differences in incidences could be
due to the different geographical coverage and the coding which
differed between the databases [18].
In the UK, there were no cases of pneumonia after pertussis
diagnosis in the vaccinated cohort that comprised more than
900,000 children. In RCGP RSC, pneumonia is one of the conditions
specifically monitored and the participating practices receive feed-
back about their data quality for this conditions, so it is likely that
the data are reliable [19]. The HRs for pneumonia following pertus-
sis in vaccinated children was similar in Denmark and Spain with
overlapping 95% CIs. The rates of pneumonia following pertussis
in our vaccinated cohorts, where this could be calculated were sim-
ilar to previously reported rates of between 0 and 3% [20,21]. The
generalised convulsion rates in the vaccinated cohorts were extre-
mely low and available in only two databases. The numbers of
cases of generalised convulsions and death after pertussis in vacci-
nated children in the participating databases were too low to allow
accurate interpretation.
The trends of estimated IRs were coherent with those from
national surveillance databases based on confirmed pertussis.
Our analysis included all pertussis cases (both suspected and con-
firmed). No chart reviews or specific analyses on confirmed or sus-
pected cases were performed for pertussis but the predictive
values were previously checked for some complications, such as
pneumonia, in BIFAP database [22]. It was not possible to make
appropriate and reliable comparisons with the IRs for pertussis
and pertussis-related complications in the literature because the
Fig. 2. Incidence of pertussis according to the type and number of vaccine doses received.
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available. Although comparison of IR among databases for the out-
comes studied in the ADVANCE project by age, calendar year and
sex were performed in order to assess the external validation as
a first step before the analytical studies (Ref to fingerprint paper),
the databases included in our study were from different clinical
settings (GP only, hospital only or hospital and GP) and with differ-
ent coding comportments (at regional or national levels), thus only
the comparison of the trends over the time for estimates of pertus-
sis incidence and pertussis-related complication rates seemed to
be meaningful [18].
However, it is important to remember that the purpose of this
POC study was to assess the methodological aspects of the design,
conduct and reporting of studies for vaccine benefit-risk monitor-
ing activities through the distributed data network the proposed
by ADVANCE which is similar to that developed in the United
States [2]. Although the vaccine effectiveness and the impact of
vaccination programmes were not fully evaluated, we estimated
the incidence of pertussis over time in vaccinated children as well
as the incidence rate per dose, which, by some means, indicated
the benefits of pertussis vaccines. The results, however, are not
intended to inform regulatory or clinical decisions.
In conclusion, our results demonstrate the feasibility of estimat-
ing incidence rates for specific pertussis and pertussis-related com-
plications outcomes using the ADVANCE distributed data system in
the databases included in this study. Due to the low incidences ofpertussis-related complications, larger sample sizes and inclusion
of more databases would provide additional power.
Disclaimer
The results described in this publication are from the proof of
concept studies conducted as part of the IMI ADVANCE project
with the aim of testing the methodological aspects of the design,
conduct and reporting of studies for vaccine benefit-risk monitor-
ing activities. The results presented relate solely to the method-
ological testing and are not intended to inform regulatory or
clinical decisions on the benefits and risks of the exposures under
investigation. This warning should accompany any use of the
results from these studies and they should be used accordingly.
The views expressed in this article are the personal views of the
authors and should not be understood or quoted as being made
on behalf of or reflecting the position of the agencies or organisa-
tions with which the authors are affiliated.
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Table 3
Pertussis-related complications in children who had received at least one dose of pertussis vaccine compared with matched controls.
Data source
(country)
Study group Pneumonia (within one month) Generalised convulsions (within
one month)





Yes No Hazard ratio
(95% CI)
AUH (Denmark) Reference cohort aP 11 6789 18.6 (4.1; 84.0) 9 6791 NA 1 6799 NA
Pertussis cohort aP 2 66 0 68 0 68
SSI (Denmark) Reference cohort aP 313 200,387 24.6 (19.1; 31.7) 251 200,499 1.99 (0.8; 4.8) 45 200,655 NA
Pertussis cohort - aP 75 1932 5 2002 0 2007
RCGP RSC (UK) Reference cohort aP or wP 8 10,871 NA 18 10,861 NA 0 10,879 NA
Pertussis cohort - aP 0 41 0 41 0 41
Pertussis cohort wP 0 115 0 115 0 115
THIN (UK) Reference cohort aP or wP 6 43,953 NA 13 43,946 NA 6 43,953 NA
Pertussis cohort - aP 0 182 0 182 0 182
Pertussis cohort wP 0 261 0 261 0 261
BIFAP (Spain) Reference cohort aP or wP 77 27,991 15.4 (3.6; 66.3) 30 28,038 NA 4 28,064 NA
Pertussis cohort - aP 2 306 0 308 0 308
Pertussis cohort wP 0 3 0 3 0 3
SIDIAP (Spain) Reference cohort aP 242 161,358 4.1 (2.2; 7.8) 43 161,557 4.6 (1.1; 19.2) 18 161,582 NA
Pertussis cohort aP 10 1608 2 1616 0 1618
PEDIANET (Italy) Reference cohort aP 18 2482 NA 1 2499 NA 0 2500 NA
Pertussis cohort aP 0 29 0 29 0 29
NA: could not be estimated; * 5 pertussis non-exposed children were matched for each pertussis exposed child.
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